1. Pink Sheet
  2. >>Pathways & Standards
  3. >>User Fees

US FDA Exploring Furlough Possibility If User Fee Bill Not Enacted In Time

 
• By Derrick Gingery

Furloughs would allow affected FDA staff to remain employed, while a layoffs would require affected workers to be rehired.

Furlough stamp
Furloughing employees could be more advantageous for the FDA than official layoffs if the user fee programs are not renewed in time. • Source: Shutterstock

The US Food and Drug Administration may try to classify a late user fee reauthorization as a temporary work stoppage rather than a permanent separation for thousands of its employees.

Officials at the US Food and Drug Administration are exploring the possibility of furloughing employees instead of laying them off should Congress fail to pass a user fee reauthorization package

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

Pink Sheet Podcast: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns

 
• By Derrick Gingery, Sue Sutter, and Nielsen Hobbs

Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

US FDA User Fee Collection Safe In Preliminary Trump 2026 Budget Plan

 
• By Cathy Kelly

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

Missing BsUFA Revenue Trigger Could Open US FDA Staff To Criminal Penalty

 
• By Derrick Gingery

Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.

More from Pathways & Standards